Finance

Lists
Why is SGRY up 3.09%?
Dive Deeper
SGRY:NASDAQ
Surgery Partners Inc
$13.66
+3.09%
(+0.41) 1D
$13.66
0.00% (0.00)
After hours
Closed: Sep 21, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SGRY...
Open
$13.41
High
$13.74
Low
$13.08
Mkt. cap
1.79B
Avg. vol.
2.53M
Volume
2.31M
52-wk high
$23.44
52-wk low
$11.41
EPS
-$0.69
Beta
1.92
Shares outstanding
130.92M
No. of employees
16K
Open
$13.41
High
$13.74
Low
$13.08
Mkt. cap
1.79B
Avg. vol.
2.53M
Volume
2.31M
52-wk high
$23.44
52-wk low
$11.41
EPS
-$0.69
Beta
1.92
Shares outstanding
130.92M
No. of employees
16K
News stories
From web sources and news partners
About Surgery Partners Inc
CEO-
Employees16K
Founded2004
Headquarters-
SectorHealth care provider
Websitesurgerypartners.com
Analyst ratings
Based on 9 analysts giving stock ratings to SGRY in the past 3 months
Buy
Buy
6
Hold
3
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for SGRY in the last 3 months.
Highest
Current $13.66
$24.00 (+75.70%)
Average
$18.50 (+35.43%)
Lowest
$14.00 (+2.49%)
Analyst
Recommendation
Action
Price target
Projected
Date
Joanna Gajuk
Bank of America Securities
Buy
Reiterated
$20.00
+46.4%
09/18/2026
Ryan Langston
TD Cowen
Buy
Reiterated
$19.00
+39.1%
09/18/2026
Benjamin Rossi
J.P. Morgan
Hold
Reiterated
$15.00
+9.8%
09/14/2026
Andrew Mok CFA
Barclays
Hold
Maintained
$14.00
+2.5%
08/28/2026
Bill Sutherland
Benchmark Co.
Buy
Reiterated
$24.00
+75.7%
08/11/2026
Sarah James
Cantor Fitzgerald
Buy
Maintained
$18.00
+31.8%
08/10/2026
Ben Hendrix
RBC Capital
Buy
Maintained
$19.00
+39.1%
08/10/2026
Matthew Gillmor CFA
KeyBanc
Hold
Maintained
-
-
08/11/2026
Gary Taylor
TD Cowen
Buy
Reiterated
$19.00
+39.1%
08/11/2026
Ann Hynes
Mizuho Securities
Buy
Maintained
$19.00
+39.1%
07/13/2026
Brian Tanquilut
Jefferies
Buy
Maintained
$17.00
+24.5%
05/06/2026
A.J. Rice
UBS
Buy
Maintained
$21.00
+53.7%
03/10/2026
Last report
Aug 10, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$0.10 / $0.06
+59.57%beat
Revenue / Est. (USD)
848.90M / 830.32M
+2.24%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
821.50M
885.00M
810.90M
848.90M
Cost of goods sold
626.20M
672.80M
650.70M
658.70M
Cost of revenue
626.20M
672.80M
650.70M
658.70M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
22.40M
23.70M
39.30M
36.30M
Operating expense
60.20M
78.70M
76.10M
73.70M
Total operating expenses
686.40M
751.50M
726.80M
732.40M
Operating income
135.10M
133.50M
84.10M
116.50M
Other non operating income
1.60M
8.10M
-
1.40M
EBT including unusual items
30.80M
42.60M
-3.30M
32.30M
EBT excluding unusual items
65.40M
72.50M
19.10M
53.10M
Income tax expense
5.50M
13.60M
-1.20M
2.60M
Effective tax rate
17.86%
31.92%
36.36%
8.05%
Other operating expenses
-1.70M
-4.90M
-1.70M
-1.90M
Net income
-22.70M
-15.00M
-35.90M
-15.00M
Net profit margin
-2.76%
-1.69%
-4.43%
-1.77%
Earnings per share
0.13
0.12
-0.03
0.10
Interest and investment income
-
-
-
-
Interest expense
-76.50M
-75.70M
-69.10M
-71.20M
Net interest expenses
-76.50M
-75.70M
-69.10M
-71.20M
Depreciation and amortization charges
39.50M
59.90M
38.50M
39.30M
EBITDA
174.60M
193.40M
122.60M
155.80M
Gain or loss from assets sale
15.60M
11.40M
4.30M
2.40M
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps